Advanced Bladder Cancer VL

EV-302 Subgroup Analysis: Improved Outcomes for Cisplatin-Ineligible Advanced Urothelial Cancer Patients - Michiel Van der Heijden

Details
Zach Klaassen discusses the findings of the EV-302/KEYNOTE-A39 trial with Michiel Simon Van der Heijden. The trial addresses a critical gap in treatment for cisplatin-ineligible patients with advanced urothelial cancer. Historically, these patients, who often receive carboplatin-based chemotherapy, have faced poorer outcomes compared to those eligible for cisplatin. The EV-302 trial, however, trea...

SunRISe-2 Trial: TAR-200 and Cetrelimab vs. Chemoradiotherapy for Muscle-Invasive Bladder Cancer - Stephen Williams

Details
Sam Chang and Stephen Williams discuss the ongoing SunRISe-2 trial, a phase three study targeting muscle-invasive bladder cancer (MIBC). Dr. Williams details the trial's innovative approach using TAR-200, a device for sustained gemcitabine release directly into the bladder, combined with cetrelimab, a PD-1 antibody. The goal is to offer a bladder-preserving treatment option for patients who are in...

Antibody-Drug Conjugates in Advanced Urothelial Cancer: Current Landscape and Future Directions - Matthew Galsky & Neal Shore

Details
Ashish Kamat hosts a discussion with Matthew Galsky and Neal Shore on the latest advancements in antibody-drug conjugates (ADCs) for bladder cancer. Dr. Galsky provides an overview of ADCs, highlighting the components and mechanisms of enfortumab vedotin and sacituzumab govitecan, and discusses promising results from recent trials. He also touches on emerging targets like HER2 and their potential...

Innovative Trials Highlight Progress in Treating Urothelial Carcinoma at AUA 2024 - Karim Chamie

Details
Sam Chang interviews Karim Chamie about pivotal clinical trials in urothelial carcinoma presented at AUA 2024. Dr. Chamie discusses the MoonRISe-1 trial, a Phase III study on TAR-210 (an erdafitinib intravesical delivery system) for intermediate-risk non-muscle-invasive bladder cancer, highlighting its innovative approach and potential to change the treatment landscape. He also reviews the SunRISe...

AUA 2024 Urothelial Carcinoma Highlights - Woodson Smelser

Details
Sam Chang interviews Woodson Smelser to discuss takeaways from the AUA Annual Meeting in urothelial carcinoma, highlighting the rapid advancements in non-muscle invasive bladder cancer therapies. He emphasizes the importance of new FDA-approved agents like Pembrolizumab, Nadofaragene, and Nogapendekin. Dr. Smelser also reviews clinical trials, such as the TAR-200 device and the CG0070 adenovirus....

Pembrolizumab + Chemoradiation vs. Trimodality Therapy for Muscle-Invasive Bladder Cancer: The KEYNOTE-992 Trial - Neal Shore

Details
Sam Chang interviews Neal Shore about the KEYNOTE-992 trial comparing immunotherapy combined with chemoradiation to standard trimodality therapy for muscle-invasive bladder cancer. Dr. Shore explains that the trial evaluates Pembrolizumab with chemoradiation versus placebo with chemoradiation in patients suitable for bladder-sparing approaches. He emphasizes the importance of offering bladder-pres...

Treatment Options for Advanced Urothelial Cancer Post-EV-302 - Shilpa Gupta & Karima Oualla

Details
Pat Hensley discusses first-line systemic therapy selection for advanced urothelial carcinoma with Karima Oualla and Shilpa Gupta. They highlight cisplatin-based chemotherapy as the traditional mainstay but shift focus to the EV-302 trial, which explores enfortumab vedotin (EV) and pembrolizumab (pembro) as a new first-line combination. Dr. Oualla explains the mechanisms and significant efficacy o...

Stool Microbiome Signature Predicts Response to Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer - Filippo Pederzoli & Massimo Alfano

Details
Alicia Morgans hosts a discussion with Massimo Alfano and Filippo Pederzoli on the promising link between the stool microbiome and the effectiveness of neoadjuvant pembrolizumab in treating muscle-invasive bladder cancer. This intriguing connection explores how the microbiome could serve as a predictive biomarker for immunotherapy outcomes. Dr. Alfano credits the genesis of their research to prior...

EV-302 Subgroup Analyses: Enfortumab Vedotin + Pembrolizumab Effective Across Patient Subsets in Metastatic Urothelial Cancer - Jonathan Rosenberg

Details
Alicia Morgans introduces Jonathan Rosenberg who discusses the EV-302 trial. This Phase III trial, which Dr. Rosenberg explains, involved a comparison between enfortumab vedotin (EV) combined with pembrolizumab and traditional chemotherapy for untreated metastatic urothelial cancer patients. The results were striking, with a notable improvement in both progression-free and overall survival for pat...

Navigating the Shift to Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Cancer: Key Considerations for Clinicians - Cora Sternberg

Details
Cora Sternberg discusses the significant advancement in the treatment of urothelial carcinoma, focusing on enfortumab vedotin (EV) in combination with pembrolizumab. This combination, recently approved in the US as a first-line therapy, has shifted the treatment paradigm, offering a potent alternative to traditional platinum-based therapies. Dr. Sternberg highlights the importance of this developm...